Actively Recruiting
Randomized, Double-Blind, Placebo-Controlled Phase Ib Study Evaluating SKB575 Injection for Adults With Asthma
Led by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Updated on 2026-09-10
36
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating SKB575 HBM7575 in adults aged 18 to 70 with asthma to assess its safety, tolerability, effectiveness, pharmacokinetics, pharmacodynamics, and immune response. This phase Ib study is randomized, double-blind, and placebo-controlled to provide reliable information about SKB575 compared to placebo. The study is sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and aims to treat asthma symptoms and lung function. Participants receive either SKB575 or a placebo through subcutaneous injections. The study uses a parallel design with random assignment to one of the two groups. Participants continue their stable asthma controller medications during the study without changes to their dose or regimen. The treatment period lasts up to 32 weeks, during which multiple assessments are conducted. Throughout the study, participants undergo regular evaluations including lung function tests like forced expiratory volume in one second FEV1, fractional exhaled nitric oxide FeNO measurements, asthma control questionnaires ACQ-5, and blood tests for eosinophil counts, drug levels, and antibodies against SKB575. Researchers monitor adverse events and serious adverse events from the start through week 32. The total study duration for each participant is approximately 32 weeks, with ongoing safety and efficacy assessments.
CONDITIONS
Brief Title
A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma
Research Team
X
Xin Li, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here